This website is intended for Healthcare Professionals in India only.
Adapted from Powles 2021.2
*The safety population included all patients who received any amount of trial drug. Included are TRAEs that occurred in at least 20% of patients in either treatment group or TRAEs of Grade 3 or higher that occurred in at least 5% of patients in either treatment group. TRAEs are those for which there is a reasonable possibility that they were caused by the trial treatment, as assessed by the investigator. If data regarding the relationship to treatment were missing, the event was considered to be related to treatment.2
†A total of 113 patients (55 in the PADCEV group and 58 in the chemotherapy group) had preexisting peripheral neuropathy.2
Proactively monitoring for potential AEs is an important part of effective dosing management with PADCEV. Encouraging open dialogue helps support continuity of care and appropriate dose modifications when needed.3,4
To address and manage patient anxiety about actively reporting AEs, it may help to follow this 4-step communication approach with every PADCEV patient:
1L - first-line; 2L - second-line; AE - adverse event; AR - adverse reactions; MoA - mechanism of action; TEAE - treatment-emergent adverse event; TRAE - treatment-related adverse event
References
PADCEV, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy.
PADCEV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.
